Document is current
Any future updates will be listed below
-
Authors
Cunha, Mateus Trinconi https://orcid.org/0000-0001-9101-8553
Gouveia, Mariana Carvalho
Neto, Felippe Lazar
Testa, Laura
Hoff, Paulo Marcelo
de Azambuja, Evandro
Bonadio, Renata Colombo
- License Information
-
More Information
Article History
Received: 17 July 2023
Revised: 30 October 2023
Accepted: 13 November 2023
First Online: 27 November 2023
Competing interests
: MTC, MCG, FLN, and PMH declare no competing interests. LT: Consulting or Advisory Role: Lilly, Novartis, MSD, AstraZeneca, Daiichi-Sankyo; Educational Support: Pfizer, Lilly, Zodiac, AstraZeneca; Speaker: Novartis, Roche, Pfizer, Zodiac, Lilly, MSD, AstraZeneca, Daiichi-Sankyo; Institutional Research Funding: Novartis. RCB: Speaker fees and/or honoraria for consulting or advisory functions: Daiichi-Sankyo, Nestle Health Science, Zodiac, Gilead, MSD. Expert testimony: AstraZeneca, Ache, Nestle Health Science. Financial support for educational programs and symposia: AstraZeneca, Daiichi-Sankyo. Institutional—Research grant: Novartis, AstraZeneca. EA: Financial: Honoraria and/or advisory board from Roche/GNE, Novartis, SeaGen, Zodiac, Libbs, Pierre Fabre, Lilly, AstraZeneca, MSD, Gilead Sciences; Travel grants from Roche/GNE and AstraZeneca; Research grant to my institution from Roche/GNE, AstraZeneca, and GSK/Novartis, Gilead Sciences; Non-financial: ESMO director of Membership 2023–2024; BSMO President 2023–2026.
